Nørskov Kristina Holmegaard, Schjoedt Ida, Tolver Anders, Jarden Mary
Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen Ø 2100, Denmark.
Department of Mathematical Sciences, University of Copenhagen, Copenhagen N 2200, Denmark.
Sex Med. 2024 Sep 13;12(4):qfae053. doi: 10.1093/sexmed/qfae053. eCollection 2024 Aug.
Patients who undergo treatment for hematologic malignancies may experience a decline in sexual health, alterations in sexual functioning, and reproductive capacity during survivorship.
This study investigated the prevalence of sexual dysfunction and factors influencing sexual activity and functioning in patients with hematologic malignancies, to identify potential targets for interventions in clinical practice.
This nationwide cross-sectional study included adult patients diagnosed with a hematologic malignant disease in Denmark in the period from January 20, 2013, to August 20, 2022. Eligible participants received electronic questionnaires through their officially assigned digital mailbox.
Outcomes included the Female Sexual Function Index, International Index of Erectile Function, Female Sexual Distress Scale-Revised, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Sexual Health, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
A total of 362 patients, on average 5.7 ± 3.4 years postdiagnosis, completed the questionnaires. Of these, 52.5% women and 73.2% men reported sexual dysfunction, with more women (40.9%) than men (34.1%) being sexually inactive. Across gender, this was significantly more prevalent in patients >65 years of age and in those with a low quality of life. In addition, for women a significant association with fatigue and sleep difficulties was observed. In total, 40.3% reported sexual-related personal distress, with the highest proportion among patients 40 to 65 years of age. Most patients (98.7%) with sexual dysfunction had not discussed sexual issues with their healthcare professional.
It is hoped that knowledge from this study will help healthcare professionals in clinical practice and encourage them to proactively address and discuss sexual health issues with their patients, irrespective of age.
Sexually inactive participants may reduce the overall score of sexual function in the scoring of both the Female Sexual Function Index and International Index of Erectile Function. We therefore analyzed sexual function in a subgroup analysis in only those being sexually active to emphasize that level of dysfunction persists in sexually active participants.
Patients report a high prevalence of sexual dysfunction, sexual distress, and gender-specific sexual symptoms following diagnosis and treatment of a malignant hematologic disease, impacting their quality of life.Sexual Health in Patients With Hematologic Malignancies; NCT05222282; https://clinicaltrials.gov/study/NCT05222282.
接受血液系统恶性肿瘤治疗的患者在生存期可能会出现性健康下降、性功能改变和生殖能力变化。
本研究调查血液系统恶性肿瘤患者性功能障碍的患病率以及影响性活动和性功能的因素,以确定临床实践中的潜在干预靶点。
这项全国性横断面研究纳入了2013年1月20日至2022年8月20日期间在丹麦被诊断患有血液系统恶性疾病的成年患者。符合条件的参与者通过其官方指定的数字邮箱接收电子问卷。
共362例患者完成了问卷,诊断后平均5.7±3.4年。其中,52.5%的女性和73.2%的男性报告存在性功能障碍,性功能未恢复的女性(40.9%)多于男性(34.1%)。在所有性别中,65岁以上患者和生活质量较低的患者中这种情况更为普遍。此外,观察到女性性功能障碍与疲劳和睡眠困难显著相关。共有40.3%的患者报告有性相关的个人困扰,40至65岁的患者中这一比例最高。大多数性功能障碍患者(98.7%)未与医护人员讨论过性问题。
希望本研究的结果能帮助临床实践中的医护人员,并鼓励他们主动与患者讨论性健康问题,无论患者年龄大小。
性功能未恢复的参与者可能会降低女性性功能指数和勃起功能国际指数评分中的性功能总分。因此,我们仅在性功能恢复的亚组分析中分析性功能,以强调性功能障碍在性功能恢复的参与者中仍然存在。
患者报告在恶性血液系统疾病诊断和治疗后性功能障碍、性困扰及性别特异性性症状的患病率较高,影响了他们的生活质量。血液系统恶性肿瘤患者的性健康;NCT05222282;https://clinicaltrials.gov/study/NCT05222282